

CURRICULUM VITAE

Andrew J. Cutler, M.D.

Florida Clinical Research Center, LLC
3914 State Road 64 East
Bradenton, FL 34208
Tel. (941) 782-4600

CONTACT INFORMATION:

Site Selection and Information:

Bobbie Theodore, Site Liaison

Tel. (866) 669-0234

Fax (208) 575-3169

Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Florida Clinical Research Center at LifeStream Behavioral Center
Leesburg, Florida 34748

Florida Clinical Research Center
Maitland, FL 32751

Florida Clinical Research Center – Outpatient Facility
Lady Lake, FL 32159

Manatee Glens
Bradenton, Florida 34208

EDUCATION:

1983 Bachelor of Science in Biology
Haverford College, Philadelphia, Pennsylvania

1989 Doctor of Medicine
University of Virginia, School of Medicine, Charlottesville, Virginia

RESIDENCIES:

1989 - 1993 Residency in Internal Medicine
University of Virginia, Health Sciences Center, Charlottesville, Virginia

1990 - 1994 Residency in Psychiatry
University of Virginia, Health Sciences Center, Charlottesville, Virginia

CERTIFICATION:

Certified Position Investigator (CPI), Association of Clinical Research Professionals (ACRP) 2005
American Board of Psychiatry and Neurology, October 1995
American Board of Internal Medicine, December 1993

LICENSURE:

Florida Medical License: July, 1995, No. ME 0068720
Drug Enforcement Agency License: Number available on request

PROFESSIONAL EXPERIENCE:

Courtesy Assistant Professor, Department of Psychiatry, 2007 - Present
University of Florida, Gainesville, FL

Medical Director, President & Investigator, 1998 - Present
Florida Clinical Research Center LLC, Central Florida

Directs and oversees operations. Responsible for training all investigators/clinical staff. Functions as the, or under the direction of the, Principal Investigator for assigned studies performing medical oversight for study subjects.

Clinical Assistant Professor,
Department of Psychiatry and Behavioral Medicine, 1999 - Present
University of South Florida, Tampa, Florida

Instructor, Department of Psychology, 1999 - Present
University of Central Florida, Orlando, Florida

Medical Director/Director of Psychopharmacology Research, 1998 - 2002
Lakeside Alternatives Behavioral Healthcare Systems, Orlando, Florida

Co-Medical Director/Co-Director of Psychopharmacology Research, 1996 - 1998
Psychiatric Institute of Florida, Orlando, Florida

Director of Psychiatric Medicine and Psychiatry Grand Rounds, 1995 - 1996
Florida Hospital South, Orlando, Florida

Director of Consultation-Liaison Psychiatry, Department of Psychiatry, 1994 - 1995
University of Chicago, Biologic Sciences Division, Chicago, Illinois

Director of Adult Inpatient Services, Department of Psychiatry, 1994 - 1995
University of Chicago, Biologic Sciences Division, Chicago, Illinois

CLINICAL TRIAL EXPERIENCE:

Director of Psychiatric Medicine, Department of Psychiatry, 1994 - 1995
University of Chicago, Biologic Sciences Division, Chicago, Illinois

Assistant Professor, Department of Psychiatry, 1994 - 1995
University of Chicago, Biologic Sciences Division, Chicago, Illinois

ADHD

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of XXX with an Open Label Extension in Adolescents with Attention-Deficit Hyperactivity Disorder (ADHD).

A Phase III, Multi-Center, 12-Month, Open Label Safety Study of XXX in Adults with Attention-Deficit Hyperactivity Disorder.

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of XXX in Adults with Attention-Deficit Hyperactivity Disorder.

A 12-Month Open Label Study of XXX in Children with Attention Deficit Hyperactivity Disorder

A 12-Month, Open Label Study of XXX in Adults with Attention Deficit Hyperactivity Disorder

A Multi-Center, Double-Blind, Three Arm, Parallel-Group Study Comparing the Efficacy of Immediate Release XXX and Modified Release with Placebo in Children with Attention Deficit Hyperactivity Disorder

A Multi-Center, Open Label Trial of the Safety of XXX for 12 Months in Adults with Attention Deficit Hyperactivity Disorder

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Four Weeks' Duration of the Efficacy and Safety of Three Doses of XXX Compared to Placebo in Adults with Attention Deficit Hyperactivity Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX in Children with Attention Deficit Hyperactivity Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX in Adults with Attention Deficit Hyperactivity Disorder

CLINICAL TRIAL EXPERIENCE (continued):

Anxiety

A Randomized, Double-Blind, Placebo and Active Comparator Controlled, Parallel-Group Safety and Efficacy Study of XXX in Adults with Generalized Anxiety Disorder

A Long-Term, Open Label Safety and Efficacy Study of XXX in Adults with Generalized Anxiety Disorder.

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Flexible Dosing Regimens of XXX in Subjects with SDM-IV Defined Generalized Anxiety Disorder.

An Eight-Week, Double-Blind, Placebo-Controlled, Multi-Center Study with XXX (10mg Qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of XXX (350 mg Q12) in Outpatients with Generalized Anxiety Disorder.

A Double-Blind Placebo-Controlled Study of XXX in the Treatment of Adults with ADHD and Comorbid Social Anxiety Disorder.

A Four-Week Double-Blind Placebo and Active Controlled Dose Ranging Study of XXX, Three Doses and XXX in Outpatients with GAD

A Four-Week, Double-Blind, Placebo and Active Controlled, Dose-Ranging Study of XXX, Three Doses (5,15,50 mg/day) and XXX (3mg/day) in Outpatients with Generalized Anxiety Disorder

A Double-Blind, Placebo-Controlled Study of XXX in Children and Adolescents with Generalized Anxiety Disorder

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed Dose Study of the Efficacy, Safety and Tolerability of 60mg XXX Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder

A Flexible Dose Comparison of the Safety and Efficacy of XXX and Placebo in the Treatment of Generalized Anxiety Disorder

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of XXX as Add-On Therapy with XXX or XXX in the Treatment of Acute Mania

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Treatment of Hospitalized Patients with Acute Mania

CLINICAL TRIAL EXPERIENCE (continued):

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Doses of XXX in the Treatment of Hospitalized Patients with Acute Mania

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Two Fixed Doses of XXX in the Treatment of Hospitalized Patients with Acute Mania

A Multi-Center, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of XXX as Add-On Therapy with XXX or XXX in the Treatment of Acute Mania

A Phase III, Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment with Oral XXX in Subjects with Mania Who Are Receiving XXX

A Randomized, Double-Blind, XXX-and Placebo-Controlled Study of the Efficacy and Safety of XXX in Outpatients with Generalized Anxiety Disorder

Study Evaluating the Safety and Outcome of Treatment with Oral XXX in Subjects with Mania Who Are Receiving XXX

An Open Label Extension Study of the Safety and Efficacy of XXX in Patients with Generalized Anxiety Disorder

An Open Label Study of the Safety, Tolerability and Efficacy of up to 90mg XXX in Patients with Generalized Anxiety Disorder

Study of XXX in the Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia

The Efficacy and Safety of Single Dose Ranges of XXX vs. Placebo in the Treatment of Manic Episodes Associated with Bipolar Disorder I

A Double-Blind, Multi-Center, Placebo-Controlled Study of XXX 1.5 mg BID to 4.5 mg BID vs. XXX in the Treatment of Outpatients with Generalized Anxiety Disorder

Bipolar Depression

A Multi-Center Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study of XXX in the Treatment of Depression in Outpatients with Bipolar Disorder.

A Multi-Center, Double-Blind, Randomized Placebo-Controlled Double-Dummy Trial of the Use of XXX in the Treatment of Patients with Bipolar Depression

CLINICAL TRIAL EXPERIENCE (continued):

Bipolar Disorder

A Three-Week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended Release XXX in XXX Failure Patients with Bipolar Disorder

A Three-Week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of XXX in the Treatment of Bipolar Disorder

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of XXX Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open Label Extension

A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual XXX vs. XXX and Placebo In-Patients with an Acute Manic Episode

A Double-Blind, Nine-Week Extension Study Evaluating the Safety and Maintenance of Effect of XXX vs. XXX in the Treatment of Subjects with Acute Mania.

A Phase IIIb, Open Label Observational Safety Study of Extended-Release XXX Used in Combination with Other Psychotropic Medications for the Treatment of Bipolar I Disorder.

A Phase IIIb, Randomized, Double-Blind, Parallel-Group Study in Bipolar I Patients to Assess the Efficacy and Safety of XXX Administered Once-Daily vs. Twice-Daily in the Treatment of Manic Symptoms.

An Extension Study to Evaluate the Long-Term Safety and Tolerability of XXX in the Treatment of Outpatients with Bipolar Disorder.

A Six-Month, Open Label, Multi-Center Study of XXX in Patients with Bipolar Disorder

A Multi-Center, Randomized, Double-Blind Study of XXX vs. Placebo in the Treatment of Acutely Manic Patients with Bipolar Disorder

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Maintenance of Treatment of Patients with Bipolar Disorder

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Maintenance of Treatment of Patients with Bipolar Disorder

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of XXX in the Maintenance Treatment of Patients with Bipolar Disorder

A Multi-Center, Randomized, Double-Blind, Study of XXX vs. Placebo in the Treatment of Acutely Manic Patients with Bipolar Disorder

CLINICAL TRIAL EXPERIENCE (continued):

A Nine-Week, Open Label, Multi-Center Trial of Flexible Dose Ranges of XXX in the Treatment of Manic Episodes Associated with Bipolar I Disorder

A Phase III, Three-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of XXX in the Treatment of Bipolar I Disorder

A Three-Week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended Release XXX in Patients with Bipolar Disorder

Comparison of the Safety and Efficacy of XXX and XXX in the Treatment of Bipolar Disorder

XXX vs. Placebo as Add-On Treatment in Subjects with Bipolar Disorder in the Outpatient Setting

XXX vs. Placebo in the Prevention of Relapse in Bipolar Disorder

XXX vs. XXX in the Treatment of Bipolar I Disorder, Manic or Mixed

Evaluation of the Safety and Efficacy of XXX Compared to Placebo and XXX in the Treatment of an Acute Manic or Mixed Episode in Patients Who Have Bipolar Disorder

Depression

A Fifty-Two Week, Multi-Center, Open Label Study Evaluating the Long-Term Safety and Tolerability of XXX in Adult and Elderly Subjects with Major Depressive Disorder.

A Two-Week, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Severe Major Depressive Disorder

A Double-Blind Comparison of the Safety and Efficacy of XXX and XXX in the Treatment of XXX Non-Responders

A Double-Blind, Multi-Center, Placebo- and Active- Controlled, Acute and Extension Study of XXX in the Treatment of Major Depressive Disorder

A Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study Evaluating the Efficacy of XXX in Patients with Major Depressive Disorder

A Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Efficacy of XXX in the Maintenance of Antidepressant Effect Inpatients with Major Depressive Disorder

A Flexible Dose Comparison of the Safety and Efficacy of XXX and Placebo in the Treatment of Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (continued):

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XXX or XXX in the Treatment of Patients with Moderate Depression

A Phase IIB, Six-Week, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Oral XXX in Outpatients with MDD

A Phase III Open Label Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features Who Have Previously Demonstrated a Rapid Response to XXX or Placebo in Study XXX or XXX

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features Who Are Not Receiving Antidepressants or Antipsychotics

A Six-Week, Double-Blind, Extension of A Phase II, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Oral XXX in Outpatients with Major Depressive Disorder

An Eight-Week, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Two Doses of XXX (1.5 mg & 3 mg) and XXX in Subjects with Major Depressive Disorder

Double-Blind, Placebo- and XXX-Controlled, Multi-Center, Dose Ranging Study Evaluating the Efficacy and Safety of XXX in Outpatients with Severe Major Depressive Disorder

Fixed Dose Study of Oral XXX and XXX in the Treatment of Outpatients with Moderate Depression

Maintenance of Antidepressant Effect of XXX in Geriatric Outpatients

XXX vs. Placebo vs. XXX in the Acute Treatment of Major Depression

A Double Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Efficacy of XXX in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder

A Phase III, Open Label Study of Safety, Tolerability, and Efficacy of the XXX in Elderly Subjects with Major Depressive Disorder

An Open Label Extension Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (continued):

Schizophrenia

A Randomized, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety and Tolerability of a 24 mg/day Dose XXX Given BID for 28 Days to Schizophrenic Patients in Acute Exacerbation Followed by a Long-Term Treatment Phase

A Six-Week, Multi-Center, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained Release Formulation XXX and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia

A Multi-Center, Randomized, Double-Blind, Fixed-Dose, Six-Week Trial of the Efficacy and Safety of XXX Compared with Placebo Using XXX Positive Control in Subjects with Acute Exacerbation Schizophrenia

A Six-Week, Double-Blind, Randomized, Fixed Dose Parallel-Group Study of Efficacy and Safety of Three Dose Levels of XXX Compared to Placebo and XXX in Patients with Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms

A Controlled Trial of XXX vs. XXX in the Treatment of Schizophrenic and Schizoaffective Subjects with Prominent Negative Symptoms

A Controlled Trial of XXX vs. XXX in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression

A Double-Blind, Randomized, Fixed Dose, Placebo-Controlled, Parallel-Group, Six-Week, Efficacy, Safety and Tolerability Study of Two Dose Levels of XXX in Patients with Schizophrenia by DSM-IV Criteria Who Are Experiencing Acute Exacerbation of Symptoms

A Double-Blind, Placebo and XXX-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of XXX in Schizophrenic Patients

A Double-Blind, Randomized, Fixed Dose, Placebo-Controlled, Parallel-Group, Six-Week Efficacy, Safety, and Tolerability Study of Two Dose Levels of XXX in Patients with Schizophrenia By DSM-IV Criteria Who Are Experiencing an Acute Exacerbation of Symptoms

A Double-Blind, Randomized, Multi-Center, Parallel-Group Design Study to Evaluate the Efficacy and Safety of Two Dose Ranges of XXX in Comparison with Placebo and XXX in the Treatment of Schizophrenia

A Multi-Center, Double-Blind, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation XXX and Placebo in the Treatment of Patients with Schizophrenia

CLINICAL TRIAL EXPERIENCE (continued):

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Three Fixed Doses of XXX in the Treatment of Patients with Acute Schizophrenia

A Phase II, Six-Week, Double-Blind, Placebo- and XXX-Controlled Study Evaluating the Safety and Efficacy of Oral XXX in Schizophrenia and Schizoaffective Disorder

Open Label, Long-Term Follow-up Safety Study of XXX in Schizophrenic/Schizoaffective Patients

Open Label, Treatment Switching Study from Orally Administered Antipsychotic Mono-Therapy to Orally Administered XXX Mono-Therapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients

A Randomized, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Non-Overlapping Dose Ranges of XXX Given BIP for 42 Days to Schizophrenic Patients Followed by a Long-Term Treatment Phase with XXX Given QD

A Randomized, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Non-Overlapping Dose Ranges of XXX Given BIP For 42 Days to Schizophrenic Patients Followed by a Long-Term Treatment Phase with XXX

A Randomized, Double-Blind, Placebo-Controlled, XXX-Referenced, Dose Finding Study of XXX in the Treatment of Schizophrenia

Cost Effectiveness and Functional Outcomes XXX in the Treatment of Schizophrenia in Usual Clinical Practice: A Randomized Clinical Study

Efficacy of XXX in the Treatment of Acutely Ill Non-Compliant Schizophrenic Patients

Study of the Efficacy and Safety of XXX in Schizophrenic and Schizoaffective Patients

A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized Parallel- Group Evaluation of the Efficacy and Safety of a Fixed Dose of XXX vs. Placebo vs. XXX in Subjects with Schizophrenia

A Randomized, Open Label, Rater-Blinded, Assessment of Optimal Treatment Change Strategy to XXX for Patients Intolerant of XXX

CLINICAL TRIAL EXPERIENCE (continued):

Sleep Disorders

A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel-Groups, Efficacy and Safety Extension Study of XXX 15 mg and 10 mg in the Treatment of Adult Outpatients with Primary Insomnia.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Safety and Efficacy Study of XXX in Elderly Subjects with Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

A Phase III, Open Label, Fixed Dose Study to Determine the Safety of Long-Term Administration of XXX in Subjects with Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Safety and Efficacy Study of XXX in Adults with Chronic Insomnia

A Phase III, Open Label, Outpatient Extension Study to Assess the Long-Term Safety of a Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

Other indications

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate XXX in Patients with Alzheimer's Disease of Mild to Moderate Severity

A Randomized, Open Label, Dose Blinded, Multi-Center, Six-Month Study of Safety and Tolerability of Three Dose Levels of XXX

Comparison of Efficacy and Safety of XXX, XXX, and Placebo in the Treatment of Elderly Subjects Presenting with Alzheimer's Dementia and Psychoses or Other Selected Psychoses

Open Extension Study Evaluating the Safety and Outcome of 40-160 mg Daily of Oral XXX

Open Label Extension Study of XXX in Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia

Study of XXX (Also Known as XXX) Used in Elderly Subjects for the Prevention of Clinical Influenza During the Influenza Season